Exchange: NASDAQ·Updated 03:58 PM EDT
TERN logo

TERN Terns Pharmaceuticals Inc

$52.96
$0.03
(0.06%)
Today
Reported EarningsNov 10
Mkt Cap$6.12B

About TERN

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.
49

Neutral Sentiment

How do you feel about TERN?

Advertisement|Remove ads.